Your Article Summary
See Latest ArticlesGemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/01/09
Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors.
Methods- Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
- GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
- Follow-up for evidence of toxicity, response, and survival
- Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation
- Toxicity manageable overall
- Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
- Partial response for 3 (17%) of 18 pts
- Median progression-free survival: 7 mo
- Median overall survival: 23.4 mo
Related Articles
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Relevance Score: 95%
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Journal of Clinical Oncology, 11/13/09
Relevance Score: 93%
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Relevance Score: 93%
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09
Relevance Score: 91%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 91%
Today in Neuroendocrinology...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of antioxidant systems in pituitary-adrenal axis diseases
Pituitary, 12/18/09
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
The risk for breast cancer is not evidently increased in women with hyperprolactinemia
Pituitary, 12/18/09
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09